{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:58:33Z","timestamp":1790233113822,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.omtm.2019.11.001","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T19:53:19Z","timestamp":1573588399000},"page":"418-429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["Immunology of Adenoviral Vectors in Cancer Therapy"],"prefix":"10.1016","volume":"15","author":[{"given":"Amanda Rosewell","family":"Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2019.11.001_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omtm.2019.11.001_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jgm.2698","article-title":"Gene therapy clinical trials worldwide to 2012\u2014an update","volume":"15","author":"Ginn","year":"2013","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2019.11.001_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omtm.2019.11.001_bib4","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood-2010-03-276949","article-title":"Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in\u00a0vitro and in\u00a0vivo","volume":"116","author":"Seregin","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2019.11.001_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.omtm.2019.11.001_bib6","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1126\/science.1187996","article-title":"The molecular interaction of CAR and JAML recruits the central cell signal transducer PI3K","volume":"329","author":"Verdino","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.11.001_bib7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.immuni.2009.04.015","article-title":"Virus binding to a plasma membrane receptor triggers interleukin-1\u03b1-mediated proinflammatory macrophage response in\u00a0vivo","volume":"31","author":"Di Paolo","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.omtm.2019.11.001_bib8","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JVI.02192-06","article-title":"Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways","volume":"81","author":"Zhu","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature06013","article-title":"DAI (DLM-1\/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response","volume":"448","author":"Takaoka","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2019.11.001_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature06664","article-title":"The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response","volume":"452","author":"Muruve","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2019.11.001_bib11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/mt.2012.277","article-title":"Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in\u00a0vivo","volume":"21","author":"Suzuki","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.001_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.18632\/oncotarget.231","article-title":"The challenge for gene therapy: innate immune response to adenoviruses","volume":"2","author":"Thaci","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtm.2019.11.001_bib13","doi-asserted-by":"crossref","first-page":"e1005415","DOI":"10.1371\/journal.ppat.1005415","article-title":"E2F\/Rb family proteins mediate interferon induced repression of adenovirus immediate early transcription to promote persistent viral infection","volume":"12","author":"Zheng","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omtm.2019.11.001_bib14","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/v3060920","article-title":"Pattern recognition receptors and the innate immune response to viral infection","volume":"3","author":"Thompson","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.omtm.2019.11.001_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2019.11.001_bib16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.mt.6300031","article-title":"Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors","volume":"15","author":"Cerullo","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.001_bib17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1084\/jem.192.4.595","article-title":"Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6","volume":"192","author":"H\u00e4cker","year":"2000","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtm.2019.11.001_bib18","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/35021228","article-title":"Toll-like receptors in the induction of the innate immune response","volume":"406","author":"Aderem","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2019.11.001_bib19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ni1118","article-title":"Interferon-\u03b1 induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6","volume":"5","author":"Kawai","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib20","doi-asserted-by":"crossref","first-page":"15416","DOI":"10.1073\/pnas.0406933101","article-title":"Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling","volume":"101","author":"Honda","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2019.11.001_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1126\/science.1226625","article-title":"Coagulation factor X activates innate immunity to human species C adenovirus","volume":"338","author":"Doronin","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.11.001_bib22","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1128\/JVI.03576-14","article-title":"Human coagulation factor X-adenovirus type 5 complexes poorly stimulate an innate immune response in human mononuclear phagocytes","volume":"89","author":"Eichholz","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-065X.2008.00734.x","article-title":"Function of Nod-like receptors in microbial recognition and host defense","volume":"227","author":"Franchi","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omtm.2019.11.001_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-\u03b2","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtm.2019.11.001_bib25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2172-12-8","article-title":"Evaluation of signal transduction pathways after transient cutaneous adenoviral gene delivery","volume":"12","author":"Steinstraesser","year":"2011","journal-title":"BMC Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1089\/hum.2011.002","article-title":"NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in\u00a0vivo","volume":"22","author":"Suzuki","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.001_bib27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ni1243","article-title":"IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction","volume":"6","author":"Kawai","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib28","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/JVI.02160-10","article-title":"Adenovirus virus-associated RNAs induce type I interferon expression through a RIG-I-mediated pathway","volume":"85","author":"Minamitani","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib29","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cell.2009.06.015","article-title":"RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway","volume":"138","author":"Chiu","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2019.11.001_bib30","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1128\/JVI.02702-13","article-title":"Adenovirus detection by the cGAS\/STING\/TBK1 DNA sensing cascade","volume":"88","author":"Lam","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.11.001_bib32","doi-asserted-by":"crossref","first-page":"14426","DOI":"10.1128\/JVI.02608-14","article-title":"Unabated adenovirus replication following activation of the cGAS\/STING-dependent antiviral response in human cells","volume":"88","author":"Lam","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib33","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.omtm.2019.11.001_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.virol.2004.12.029","article-title":"Use of chimeric adenoviral vectors to assess capsid neutralization determinants","volume":"333","author":"Roy","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2019.11.001_bib35","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection","volume":"86","author":"Bradley","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib37","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/JVI.02023-06","article-title":"Structure-based identification of a major neutralizing site in an adenovirus hexon","volume":"81","author":"Pichla-Gollon","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib38","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/104303402320138952","article-title":"The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope","volume":"13","author":"Olive","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.001_bib39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.virol.2006.01.024","article-title":"Human CD8+ cytotoxic T\u00a0cell responses to adenovirus capsid proteins","volume":"350","author":"Tang","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2019.11.001_bib40","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood-2004-02-0646","article-title":"Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T\u00a0cells","volume":"104","author":"Leen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2019.11.001_bib41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fimmu.2018.00335","article-title":"Seroprevalence of neutralizing antibodies against human adenovirus type-5 and chimpanzee adenovirus type-68 in cancer patients","volume":"9","author":"Zhao","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib42","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Alemany","year":"2000","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib43","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/gt.2008.114","article-title":"Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors","volume":"15","author":"Appledorn","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.11.001_bib44","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/j.1349-7006.2010.01578.x","article-title":"Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer","volume":"101","author":"Narumi","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omtm.2019.11.001_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omtm.2019.11.001_bib46","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: a double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib47","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2019.11.001_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","article-title":"Molecular characteristics of immunogenic cancer cell death","volume":"15","author":"Tesniere","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.omtm.2019.11.001_bib49","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1111\/jcmm.14356","article-title":"Immunogenic cell death in cancer therapy: present and emerging inducers","volume":"23","author":"Zhou","year":"2019","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.omtm.2019.11.001_bib50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fimmu.2017.00555","article-title":"Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives","volume":"8","author":"Guo","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1172\/JCI200420278","article-title":"Specifically activated memory T\u00a0cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors","volume":"114","author":"Beckhove","year":"2004","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2019.11.001_bib52","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.4049\/jimmunol.1402711","article-title":"CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T\u00a0cells and a prognostic factor for survival in lung cancer patients","volume":"194","author":"Djenidi","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/1078-0432.CCR-16-0477","article-title":"The Efficacy of oncolytic adenovirus is mediated by t-cell responses against virus and tumor in Syrian hamster model","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib54","doi-asserted-by":"crossref","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omtm.2019.11.001_bib55","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gut.2009.196519","article-title":"Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma","volume":"59","author":"Boozari","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.omtm.2019.11.001_bib56","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fonc.2019.00564","article-title":"The oncolytic virus dl922-947 triggers immunogenic cell death in mesothelioma and reduces xenograft growth","volume":"9","author":"Di Somma","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtm.2019.11.001_bib57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.omto.2016.11.003","article-title":"Oncolytic group B adenovirus enadenotucirev mediates non-apoptotic cell death with membrane disruption and release of inflammatory mediators","volume":"4","author":"Dyer","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omtm.2019.11.001_bib58","doi-asserted-by":"crossref","first-page":"1591875","DOI":"10.1080\/2162402X.2019.1591875","article-title":"Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma","volume":"8","author":"Bommareddy","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omtm.2019.11.001_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02145-17","article-title":"Virulent poxviruses inhibit DNA sensing by preventing STING activation","volume":"92","author":"Georgana","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib60","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvirnment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2019.11.001_bib61","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1099\/0022-1317-75-10-2765","article-title":"Short and long term dissemination of deletion mutants of adenovirus in permissive (cotton rat) and non-permissive (mouse) species","volume":"75","author":"Oualikene","year":"1994","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-398342-8.00003-3","article-title":"Chapter three\u2014Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds","volume":"115","author":"Wold","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib63","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/JVI.80.7.3549-3558.2006","article-title":"Replication properties of human adenovirus in\u00a0vivo and in cultures of primary cells from different animal species","volume":"7","author":"Jogler","year":"2006","journal-title":"J.\u00a0Virol"},{"key":"10.1016\/j.omtm.2019.11.001_bib64","doi-asserted-by":"crossref","first-page":"e1136046","DOI":"10.1080\/2162402X.2015.1136046","article-title":"Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting","volume":"5","author":"Siurala","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omtm.2019.11.001_bib65","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/1078-0432.CCR-16-0477","article-title":"The efficacy of oncolytic adenovirus is mediated by T-cell responses against virus and tumor in Syrian hamster model","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.omtm.2019.11.001_bib66","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/imm.12906","article-title":"A Hitchhiker\u2019s guide to humanized mice: new pathways to studying viral infections","volume":"154","author":"Skelton","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.omtm.2019.11.001_bib68","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/infdis\/jiw499","article-title":"Humanized mice reproduce acute and persistent human adenovirus infection","volume":"215","author":"Rodr\u00edguez","year":"2017","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.omtm.2019.11.001_bib69","doi-asserted-by":"crossref","first-page":"e1490856","DOI":"10.1080\/2162402X.2018.1490856","article-title":"CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy","volume":"7","author":"Zafar","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omtm.2019.11.001_bib70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2016.06.009","article-title":"Recent advances in oncolytic adenovirus therapies for cancer","volume":"21","author":"Rosewell Shaw","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib71","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3389\/fimmu.2018.02103","article-title":"Oncolytic viruses partner with T-cell therapy for solid tumor treatment","volume":"9","author":"Rosewell Shaw","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib72","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/mt.2012.137","article-title":"An oncolytic adenovirus enhanced for Toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance","volume":"20","author":"Cerullo","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.001_bib73","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1158\/0008-5472.CAN-10-0905","article-title":"Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity","volume":"70","author":"Hartman","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib74","doi-asserted-by":"crossref","first-page":"e958937","DOI":"10.4161\/21624011.2014.958937","article-title":"Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization","volume":"3","author":"Ranki","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omtm.2019.11.001_bib75","doi-asserted-by":"crossref","first-page":"e1017702","DOI":"10.1080\/2162402X.2015.1017702","article-title":"Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer","volume":"4","author":"Vassilev","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omtm.2019.11.001_bib76","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.omtm.2019.11.001_bib77","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clim.2017.07.006","article-title":"Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients","volume":"189","author":"Lowenstein","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1215\/15228517-2007-045","article-title":"Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model","volume":"10","author":"King","year":"2008","journal-title":"Neuro-oncol."},{"key":"10.1016\/j.omtm.2019.11.001_bib80","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2019.03.001","article-title":"Oncolytic virus-based cytokine expression to improve immune activity in brain and solid tumors","volume":"13","author":"Pearl","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omtm.2019.11.001_bib81","doi-asserted-by":"crossref","first-page":"15006","DOI":"10.1038\/mto.2015.6","article-title":"Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer","volume":"2","author":"Freytag","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omtm.2019.11.001_bib82","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/mt.2009.9","article-title":"Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters","volume":"17","author":"Bortolanza","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.001_bib83","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2004.04.059","article-title":"Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors","volume":"22","author":"Sangro","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2019.11.001_bib84","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/CJI.0b013e318193d31e","article-title":"Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity","volume":"32","author":"Lapteva","year":"2009","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omtm.2019.11.001_bib85","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2019.11.001_bib86","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/187153007780059432","article-title":"CD40L\u2014a multipotent molecule for tumor therapy","volume":"7","author":"Loskog","year":"2007","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"10.1016\/j.omtm.2019.11.001_bib87","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/CJI.0b013e3181acea69","article-title":"Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition","volume":"32","author":"Lindqvist","year":"2009","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omtm.2019.11.001_bib88","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","article-title":"AdCD40L immunogene therapy for bladder carcinoma\u2014the first phase I\/IIa trial","volume":"16","author":"Malmstr\u00f6m","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib89","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/bjc.2016.42","article-title":"Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients","volume":"114","author":"Loskog","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omtm.2019.11.001_bib90","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T\u00a0cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtm.2019.11.001_bib91","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1073\/pnas.0837611100","article-title":"Effector CD8 T\u00a0cells possess suppressor function after 4-1BB and Toll-like receptor triggering","volume":"100","author":"Myers","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2019.11.001_bib92","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib93","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2019.11.001_bib94","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1158\/1078-0432.CCR-12-0979","article-title":"A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity","volume":"18","author":"Tysome","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib95","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12943-015-0479-x","article-title":"Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model","volume":"14","author":"Nistal-Villan","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omtm.2019.11.001_bib96","doi-asserted-by":"crossref","first-page":"e1445459","DOI":"10.1080\/2162402X.2018.1445459","article-title":"Transforming the prostatic tumor microenvironment with oncolytic virotherapy","volume":"7","author":"Atherton","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omtm.2019.11.001_bib97","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/2326-6066.CIR-17-0102","article-title":"Customized viral immunotherapy for HPV-associated cancer","volume":"5","author":"Atherton","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib98","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-019-11137-5","article-title":"Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy","volume":"10","author":"Niemann","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2019.11.001_bib99","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omtm.2019.11.001_bib100","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","article-title":"Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy","volume":"77","author":"Fajardo","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib101","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib102","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib103","doi-asserted-by":"crossref","first-page":"e1412902","DOI":"10.1080\/2162402X.2017.1412902","article-title":"TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade","volume":"7","author":"Cervera-Carrascon","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omtm.2019.11.001_bib104","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/jmv.25501","article-title":"Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma","volume":"91","author":"Kuryk","year":"2019","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.omtm.2019.11.001_bib105","doi-asserted-by":"crossref","first-page":"e1532763","DOI":"10.1080\/2162402X.2018.1532763","article-title":"Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model","volume":"8","author":"Kuryk","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omtm.2019.11.001_bib106","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/0008-5472.CAN-16-1577","article-title":"Armed oncolytic adenovirus-expressing PD-L1\u00a0mini-body enhances antitumor effects of chimeric antigen receptor T\u00a0cells in solid tumors","volume":"77","author":"Tanoue","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2019.11.001_bib107","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T\u00a0cells against metastatic head and neck cancer","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:25:18Z","timestamp":1762421118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050119301263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":107,"alternative-id":["S2329050119301263"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2019.11.001","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunology of Adenoviral Vectors in Cancer Therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2019.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}